TB vaccine Phase IIbtrial results encouraging: GSK

Drug major GSK and the International AIDS Vaccine Initiative (IAVI) on Tuesday said the former's vaccine candidate significantly reduced incidence of pulmonary tuberculosis disease (TB) in HIV-negative adults with latent TB infection.

These Phase IIb results demonstrate an overall vaccine efficacy of 50 per cent during the three years after vaccination. The candidate vaccine of GSK has an acceptable safety and reactogenicity profile, a press release said here.

The final results are consistent with the primary analysis done after two years of follow-up and published in New England Journal of Medicine in September 2018, it said.

The study was conducted by GSK with the partnership of IAVI.

Welcoming the Phase IIb Trial results of the tuberculosis (TB) vaccine candidate of GSK (GSK/IAVI M72), Paula I Fujiwara, Scientific Director of the International Union Against Tuberculosis and Lung Disease (The Union), on Tuesday here said We are one more cautious, but exciting, step closer to a vaccine for tuberculosis (TB)."